Bausch + Lomb saw its stock surge by 13% in Toronto, trading at 24.01 Canadian dollars (around $17.67), following a report by the Financial Times suggesting the eye care company is considering a sale. The possible sale is being considered as a way to separate from its heavily indebted parent company, Bausch Health Companies Inc. This news comes amid mounting financial pressures on Bausch Health, which is struggling with a $21 billion debt load, nearly half of which will mature by 2027. This potential move has sent shockwaves through the market, sparking speculation about the future of the renowned eye care firm and its beleaguered parent.

Possible Sale to Private Equity as a Lifeline

Bausch + Lomb, a leading name in contact lenses and eye care products, was spun off from Bausch Health in 2022. Now, it is reportedly exploring a sale to private equity firms, with Goldman Sachs acting as an advisor to gauge market interest. The sale could potentially provide a significant financial lifeline for Bausch Health, which has been struggling to manage its massive debt, accumulated due to a series of aggressive acquisitions under its previous name, Valeant Pharmaceuticals. Sources familiar with the matter suggest that private equity firms are among the potential buyers, indicating strong interest due to Bausch + Lomb’s solid market position and growth potential.

Market analysts from Wells Fargo have pointed out that a sale could be strategically beneficial given the valuation disparity between Bausch + Lomb and its competitors in the eye care sector. A sale would likely come at a premium, considering the company’s robust performance and the growing demand for eye care products globally. However, the process may face significant challenges, including regulatory hurdles and the need for Bausch Health to pass a solvency test to ensure the sale does not jeopardize its financial stability.

Concerns Over Financial Stability and Shareholder Reactions

Bausch Health, which still holds an 88% stake in Bausch + Lomb, must navigate complex financial dynamics before any potential sale can proceed. The parent company, heavily weighed down by its debt obligations, would need to prove its solvency before moving forward with any transaction involving Bausch + Lomb. The substantial debt burden has raised concerns among major creditors, including Apollo Global Management, Elliott Management, and GoldenTree Asset Management. These stakeholders have expressed apprehensions about the potential impact of a sale on the parent company’s financial health and its ability to meet debt obligations.

Meanwhile, significant shareholders like Carl Icahn and John Paulson, who hold board positions in both Bausch Health and Bausch + Lomb, have shown support for the potential sale. They believe that separating the two companies could unlock greater value and provide them with a larger share of the more profitable eye care business. However, there remains a high level of uncertainty, and not all stakeholders are aligned on this strategy.

Expert Opinions Highlight Market Optimism and Risks

Industry experts suggest that while the sale could provide a quick infusion of cash for Bausch Health, it might not fully resolve the underlying issues tied to its aggressive acquisition strategy and looming debt maturities. A senior analyst at a major investment bank commented that “the transaction could potentially strengthen Bausch + Lomb’s market position independently but may leave Bausch Health exposed to greater financial vulnerability if it fails to stabilize its cash flow and debt repayments post-sale.”

Further complicating matters, Bausch Health is also facing other challenges, including the expiration of its key drug, Xifaxan, in 2029, and ongoing legal issues concerning the drug, which have impacted investor confidence and contributed to a decline in the company’s market value to $2.2 billion.

Market Reactions and Future Outlook

Following the news of a potential sale, shares of Bausch + Lomb rose nearly 14% during intraday trading, signalling strong investor confidence in the company’s potential for a successful sale and growth prospects. Bausch Health’s shares also saw a 6% increase, reflecting cautious optimism from investors about the possibility of reducing its debt burden through the proceeds from a potential sale. Nonetheless, market experts caution that the road ahead is fraught with challenges, and the final outcome remains uncertain.

As both companies navigate these complex circumstances, the developments will be closely watched by investors, creditors, and market analysts. The unfolding situation could significantly impact the strategic direction and financial health of both Bausch + Lomb and Bausch Health.

  Apollo Global Management, Bausch + Lomb, Bausch Health, Carl Icahn, Elliott Management, GoldenTree Asset Management, Goldman Sachs, John Paulson, Valeant Pharmaceuticals, Xifaxan